BR112017001958A2 - composições de núcleo - Google Patents

composições de núcleo

Info

Publication number
BR112017001958A2
BR112017001958A2 BR112017001958A BR112017001958A BR112017001958A2 BR 112017001958 A2 BR112017001958 A2 BR 112017001958A2 BR 112017001958 A BR112017001958 A BR 112017001958A BR 112017001958 A BR112017001958 A BR 112017001958A BR 112017001958 A2 BR112017001958 A2 BR 112017001958A2
Authority
BR
Brazil
Prior art keywords
core compositions
mixture
active pharmaceutical
pharmaceutical ingredient
adsorbing
Prior art date
Application number
BR112017001958A
Other languages
English (en)
Inventor
Lee Der-Yang
Kutch Timothy
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112017001958A2 publication Critical patent/BR112017001958A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a um processo para adsorção de um ingrediente farmacêutico ativo em um substrato, compreendendo as etapas de (a) adicionar e misturar um adsorvente inerte a uma forma não sólida compreendendo o ingrediente farmacêutico ativo, formando assim uma mistura; e (b) secar a mistura para formar um material sólido quebradiço.
BR112017001958A 2014-08-01 2015-07-31 composições de núcleo BR112017001958A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462032029P 2014-08-01 2014-08-01
PCT/US2015/043127 WO2016019252A1 (en) 2014-08-01 2015-07-31 Core compositions

Publications (1)

Publication Number Publication Date
BR112017001958A2 true BR112017001958A2 (pt) 2017-11-21

Family

ID=53879786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001958A BR112017001958A2 (pt) 2014-08-01 2015-07-31 composições de núcleo

Country Status (7)

Country Link
US (1) US20160030345A1 (pt)
EP (1) EP3174527B1 (pt)
CN (1) CN106794142A (pt)
BR (1) BR112017001958A2 (pt)
CA (1) CA2956947C (pt)
RU (1) RU2017106094A (pt)
WO (1) WO2016019252A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245284B2 (en) * 2015-08-19 2019-04-02 Alpex Pharma S.A. Granular composition for oral administration
DE102016218604A1 (de) 2016-09-27 2018-03-29 Constantin Adams Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung
EP3823598A2 (en) * 2018-07-18 2021-05-26 Glatt Gmbh Immediate release formulations of cannabinoids
CN112107694B (zh) * 2020-10-30 2022-07-22 黄山中皇制药有限公司 一种喜炎平干混悬剂
CN114452262A (zh) * 2022-03-03 2022-05-10 成都恒瑞制药有限公司 一种盐酸西替利嗪片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226979A1 (en) * 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20110097414A1 (en) * 2007-02-26 2011-04-28 Sandal Roshan Lal Pharmaceutical compositions comprising adsorbate of fenofibrate
CN101380474B (zh) * 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
EP2072042A1 (en) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
US9629809B2 (en) * 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
JP2010106007A (ja) * 2008-08-14 2010-05-13 Sony Corp 薬剤徐放剤、吸着剤、機能性食品、マスク及び吸着シート
KR20110110097A (ko) * 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
CN102697761B (zh) * 2012-06-01 2013-09-04 北京大学 一种布洛芬缓释固体组合物及其制备方法

Also Published As

Publication number Publication date
CA2956947C (en) 2022-11-08
WO2016019252A1 (en) 2016-02-04
EP3174527A1 (en) 2017-06-07
CA2956947A1 (en) 2016-02-04
RU2017106094A (ru) 2018-09-04
US20160030345A1 (en) 2016-02-04
CN106794142A (zh) 2017-05-31
EP3174527B1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
IL262180A (en) Compositions for topical application of compounds
BR112015012662A2 (pt) processo para a preparação de uma composição aceleradora de endurecimento,composição aceleradora de endurecimento, uso da mesma e misturas de material de construção contendo uma composição aceleradora de endurecimento.
EP3081222A4 (en) Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
EP3478249A4 (en) STABLE MICROCAPSULE COMPOSITIONS
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
TW201614041A (en) Compositions for electronic devices
BR112017001958A2 (pt) composições de núcleo
BR112014030066A2 (pt) processo para a fabricação de uma composição de dialquil furan-2, 5-dicarboxilato (dafd), e, composição.
EP3279190A4 (en) Resist composition, method for forming resist pattern, and polyphenol compound used therein
HK1232229A1 (zh) '- '-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
EA201591085A1 (ru) Композиция с отсроченным высвобождением, содержащая бигуанид
EP3398995A4 (en) DRY MIX
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
EP3310439A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
EP3193383A4 (en) Composition for forming organic semiconductor film, organic semiconductor film and method for manufacturing same, and organic semiconductor compound
EP3335165A4 (en) Delivery mechanisms for deployment of releases of packages to endpoints
IN2014CH00840A (pt)
BR112018002798A2 (pt) Composição adsorvente, e, método para adsorção de um material arsênico
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112016009727A2 (pt) processo para a preparação de uma mistura de eteramina, e, composição
EP3039009A4 (en) Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]